Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin Followed by Familial Fecal Microbiota Transplant in ASD
NCT04630847Phase 1Not yet recruiting
- Sponsor
- ProgenaBiome
- Start
- May 2027
- Primary completion
- Jul 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in Autism Spectrum Disorder (ASD), sponsored by ProgenaBiome. Primary endpoints: Autism Treatment Evaluation Checklist at 52 weeks, Quality of Life in Autism at 52 weeks and 6 more. Planned start May 2027; status: not yet recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04630847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630847.